|
Absence of sensation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Between January 2013 and October 2016, 185 patients from two vascular units, undergoing CEA under local anaesthesia were prospectively included.
|
28431821 |
2017 |
|
Acute Cerebrovascular Accidents
|
0.010 |
Biomarker
|
disease |
BEFREE |
CEA vs stent in patients with acute strokes: are they equally effective?
|
31603298 |
2020 |
|
Acute lymphocytic leukemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
At current work, the combination of sensors were used to detect the presence of BCR-ABL1 as a mutant gene and CEA as a biomarkers of cancer, such a capability makes the package liable for early and certain detection of acute lymphoblastic leukemia.
|
31295447 |
2019 |
|
Acute lymphocytic leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CEA and CGM1 were not expressed in childhood ALLs or in the sIg+ B-cell lines.
|
7808000 |
1994 |
|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A pregnancy-specific beta 1-glycoprotein, a CEA gene family member, expressed in a human promyelocytic leukemia cell line, HL-60: structures of protein, mRNA and gene.
|
2789512 |
1989 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma.
|
29069854 |
2017 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Biopsies from the anal canal tumor, swollen lymph node, and Paget lesion all showed poorly differentiated adenocarcinoma with neuroendocrine features expressing synaptophysin and chromogranin A. Serum CEA and NSE levels were high, 809.4 ng/ml and 85.8 ng/ml, respectively.
|
30458812 |
2018 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA, CYFRA21-1 and NSE are tumor markers used for monitoring the response to chemotherapy in advanced adenocarcinoma, squamous cell carcinoma and small-cell lung cancer, respectively.
|
30849967 |
2019 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CYFRA21-1 and SCC-Ag were significantly higher in SCC, NSE was significantly higher in SCLC (P<0.001), and CEA was higher in adenocarcinoma (P = 0.343).
|
28877268 |
2017 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The positive rates for CEA in adenocarcinoma and squamous cell carcinoma patients were 23.8% and 26.8%, respectively.
|
21397974 |
2011 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CEA and NCA transcripts were, however, present in an adenocarcinoma located in the nasal sinuses.
|
7690349 |
1993 |
|
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
|
17540439 |
2007 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CEA and NSE levels were higher in adenocarcinoma and neuroendocrine tumour, respectively, while SCC-Ag and CYFRA21-1 levels were higher in squamous cell cancer.
|
30115364 |
2018 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Localization of CEA messenger RNA by in situ hybridization in normal colonic mucosa and colorectal adenocarcinomas.
|
1484322 |
1992 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of NCAM and CEA was significantly higher in adenocarcinoma subgroup than those in SqCC subgroup (45.7 and 75% vs. 14.8 and 39%, respectively).
|
11263866 |
2000 |
|
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CEA levels (P < 0.001 for DFS; P = 0.002 for OS) and clinical stage were independently predictive and prognostic in EGFR wild-type adenocarcinoma patients.
|
27072585 |
2016 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
|
24852187 |
2014 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma.
|
30724779 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.
|
24487967 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
Biomarker
|
disease |
BEFREE |
Combining hazard ratio, AUC, sensitivity, specificity, NPV, and PPV, it was concluded that CEA and CYFRA21-1were the most related TM of LAC.
|
30647803 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
Biomarker
|
disease |
BEFREE |
Expression of LDH and CEA in serum in the process of targeted therapy of lung adenocarcinoma and the association between them and prognosis.
|
30944644 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
Biomarker
|
disease |
BEFREE |
CEA, CYFRA 21-1, and CA19-9 play a role in the diagnosis of lung adenocarcinoma-associated MPE.
|
27990560 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
Biomarker
|
disease |
BEFREE |
As a control biomarker, CEA was also evaluated in lung adenocarcinoma.
|
29069748 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
|
28705152 |
2017 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Postoperative serum CA19-9, CA125 and CEA were independent risk predictors for poor surgical outcome in pancreatic adenocarcinoma (P < 0.001 for all).
|
30153903 |
2018 |